{"id":"NCT00423813","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Safety and Efficacy Study of Xyrem速 (Sodium Oxybate) to Treat Fibromyalgia.","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem速 (Sodium Oxybate) in Subjects With Fibromyalgia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2009-04","completion":"2009-06","firstPosted":"2007-01-18","resultsPosted":"2012-01-10","lastUpdate":"2012-01-24"},"enrollment":573,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"Xyrem速","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The objective of this trial is to evaluate the safety and efficacy of Xyrem速 compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.","primaryOutcome":{"measure":"Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).","timeFrame":"Baseline to Week 14","effectByArm":[{"arm":"Placebo","deltaMin":20.2,"sd":null},{"arm":"Xyrem (Sodium Oxybate) 4.5g","deltaMin":35.4,"sd":null},{"arm":"Xyrem (Sodium Oxybate) 6.0g","deltaMin":35.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":116,"countries":["United States","France","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":188},"commonTop":["Headache","Nausea","Diarrhoea","Dizziness","Nasopharyngitis"]}}